Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CFB | P00751 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478904 | 1.00 | KMT2A (0.43) | KMT2AMEN1POLBHSD11B1ALDH1A1 | |
| SCHEMBL9104352 | 1.00 | KMT2A (0.43) | KMT2AMEN1POLBHSD11B1ALDH1A1 | |
| SCHEMBL9105476 | 0.91 | ALDH1A1 (0.37) | ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL9105466 | 0.91 | ALDH1A1 (0.37) | ALDH1A1TAS1R3TAS1R1 | |
| SCHEMBL9105132 | 0.86 | DRD4 (0.39) | KMT2AMEN1 | |
| SCHEMBL9105136 | 0.86 | DRD4 (0.39) | KMT2AMEN1 | |
| SCHEMBL9103858 | 0.84 | MAPT (0.43) | — | |
| SCHEMBL9103848 | 0.84 | MAPT (0.43) | — | |
| SCHEMBL9103836 | 0.82 | KDM4E (0.40) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL9104403 | 0.82 | CYP2D6 (0.42) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | KMT2A 552/4885MEN1 482/4885POLB 4552/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | KMT2A 552/4885MEN1 482/4885POLB 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.